Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics

British Journal of Cancer

Volumn 110, Issue 5, 2014, Pages 1378-1384

  Colzani, E ^a   Johansson, A L V ^a   Liljegren, A ^b   Foukakis, T ^b   Clements, M ^a   Adolfsson, J ^a   Hall, P ^a   Czene, K ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast cancer; Competing risk; Distant metastasis; Risk; Survival analysis; Tumour characteristics

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MIDDLE AGED; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; SKELETON; TIME; TUMOR LOCALIZATION; TUMOR VOLUME; AGE; BONE METASTASIS; BREAST SURGERY; CANCER PATIENT; COHORT ANALYSIS; HAZARD RATIO; LYMPH NODE METASTASIS; RISK ASSESSMENT; RISK FACTOR; SWEDEN;

AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; RISK; SWEDEN; TIME FACTORS;

EID: 84895802666     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.5     Document Type: Article

References (33)

1. Alford SH, Toy K, Merajver SD, Kleer CG (2012) Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression. Breast Cancer Res Treat 132(2): 429-437.
2. Barlow L, Westergren K, Holmberg L, Talback M (2009) The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 48(1): 27-33.
3. Biganzoli E, Boracchi P, Coradini D, Grazia Daidone M, Marubini E (2003) Prognosis in node-negative primary breast cancer: a neural network analysis of risk profiles using routinely assessed factors. Ann Oncol 14(10): 1484-1493. (Pubitemid 37304602)
4. Brenton JD, Carey LA, Ahmed AA, Caldas C (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23(29): 7350-7360. (Pubitemid 46202348)
5. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ (2010) ASCO clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28(23): 3784-3796.
6. Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nature 2: 563-572. (Pubitemid 37328923)
7. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503): 2087-2106. (Pubitemid 41797643)
8. Colzani E, Liljegren A, Johansson AL, Adolfsson J, Hellborg H, Hall PF, Czene K (2011) Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics. J Clin Oncol 29(30): 4014-4021.
9. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA (2009a) Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status. Cancer 115(21): 4917-4923.
10. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA (2009b) Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 115(2): 423-428.
11. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1): 4429-4434. (Pubitemid 47219710)
12. Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9(1): R6.
13. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472): 1687-1717.
14. Foukakis T, Fornander T, Lekberg T, Hellborg H, Adolfsson J, Bergh J (2011) Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden. Breast Cancer Res Treat 130(2): 553-560.
15. Frisk G, Svensson T, Backlund LM, Lidbrink E, Blomqvist P, Smedby KE (2012) Incidence and time trends of brain metastases admissions among breast cancer patients in Sweden. Br J Cancer 106(11): 1850-1853.
16. Grann VR, Troxel AB, Zojvalla NJ, Jacobson JS, Hershman D, Neugut AI (2005) Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 103(11): 2241-2251. (Pubitemid 40686567)
17. Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM (1998) Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 52(1-3): 227-237. (Pubitemid 29056098)
18. Hinchliffe SR, Lambert PC (2012) Extending the flexible parametric survival model for competing risks. Stata J 12: 674-687.
19. Hsieh SM, Look MP, Sieuwerts AM, Foekens JA, Hunter KW (2009) Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study. Breast Cancer Res 11(5): R75.
20. Jensen AO, Jacobsen JB, Norgaard M, Yong M, Fryzek JP, Sorensen HT (2011) Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer 11: 29.
21. Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, Speers CH, Nielsen TO, Gelmon K (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28(20): 3271-3277.
22. Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, Hantel A, Henry NL, Muss HB, Smith TJ, Vogel VG, Wolff AC, Somerfield MR, Davidson NE (2013) Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 31(7): 961-965.
23. Lambert PC, Royston P (2009) Further developments of flexible parametric models for survival analysis. Stata J 9: 265-290.
24. Largillier R, Ferrero JM, Doyen J, Barriere J, Namer M, Mari V, Courdi A, Hannoun-Levi JM, Ettore F, Birtwisle-Peyrottes I, Balu-Maestro C, Marcy PY, Raoust I, Lallement M, Chamorey E (2008) Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol 19(12): 2012-2019.
25. Liu MT, Huang WT, Wang AY, Huang CC, Huang CY, Chang TH, Pi CP, Yang HH (2010) Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index. Support Care Cancer 18(12): 1553-1564.
26. LouwmanWJ, Voogd AC, van Dijck JA, Nieuwenhuijzen GA, Ribot J, Pruijt JF, Coebergh JW (2008) On the rising trends of incidence and prognosis for breast cancer patients diagnosed 1975-2004: a long-term population-based study in southeastern Netherlands. Cancer Causes Control 19(1): 97-106.
27. MinnAJ, Kang Y, Serganova I,GuptaGP,GiriDD,DoubrovinM, PonomarevV, Gerald WL, Blasberg R, Massague J (2005) Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 115(1): 44-55. (Pubitemid 40385504)
28. Robertson C, Arcot Ragupathy SK, Boachie C, Dixon JM, Fraser C, Hernandez R, Heys S, Jack W, Kerr GR, Lawrence G, MacLennan G, Maxwell A, McGregor J, Mowatt G, Pinder S, Ternent L, Thomas RE, Vale L, Wilson R, Zhu S, Gilbert FJ (2011) The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation. Health Technol Assess 15(34): 1-322.
29. Royston P, Parmar MK (2002) Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med 21: 2175-2197. (Pubitemid 34830755)
30. Rutqvist LE (1985) Validity of certified causes of death in breast carcinoma patients. Acta Radiol Oncol 24(5): 385-390. (Pubitemid 16177237)
31. Schneider M, Zuckerman IH, Onukwugha E, Pandya N, Seal B, Gardner J, Mullins CD (2011) Chemotherapy treatment and survival in older women with estrogen receptor-negative metastatic breast cancer: a populationbased analysis. J Am Geriatr Soc 59(4): 637-646.
32. van de Vijver M, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernard R (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25): 1999-2009. (Pubitemid 35461656)
33. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, Kunkler I (2007) Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8(9): 784-796. (Pubitemid 47321601)